Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

This study demonstrates that real-world outcomes of weekly RVD regimens have comparable efficacy to published twice-weekly regimens; however, toxicity remains a significant challenge in this patient population.